Partner for Several Innovative CNS Product Candidates TORONTO, July 8 /CNW/ - Patheon (TSX:PTI), a global provider of drug development and manufacturing services to the international pharmaceutical industry, is pleased to have been selected by SK Life Science, Inc. (formerly known as SK Bio-Pharmaceuticals), the US-based subsidiary of Korean SK Holdings as their development services partner for two additional innovative Central Nervous System (CNS) drug candidates. "We are very pleased to have been selected by SK Life Science to develop these important new drug candidates, and we look forward to continuing to provide them with exceptional service on their development projects," said Wes Wheeler, President and Chief Executive Officer of Patheon Inc. "This agreement to develop SK Life Science's two innovative candidates for the treatment of CNS disorders expands upon our existing relationship with the Company, having recently completed phase I development and clinical materials manufacturing for their next generation pain drug candidate. This agreement also demonstrates our continued commitment to provide best in class development and manufacturing services to an expanding global customer base, including the growing Korean pharmaceutical industry." "Patheon produced quality clinical materials for the pain drug project within our timelines. As a result we were very comfortable with awarding Patheon these two additional key projects," said Dr. S. James Lee, Vice President Pharmaceutical Development of SK Life Science. Patheon will provide formulation and analytical development services as well as clinical supplies for one of the CNS candidates in multiple dosage forms for SK Life Science's advanced clinical studies. In addition, Patheon will provide development and clinical materials manufacturing services for another CNS candidate in Phase I clinical trials. Both of these candidates are being developed for one of the largest pharmaceutical therapeutic categories. The global CNS market is expected to grow to $63.9 billion by 2010, according to Urch Publishing. ABOUT SK Life Science, Inc. Through its subsidiary SK Life Science, Inc. (http://pharma.sk.com), SK Holdings, Co., Ltd., the second largest conglomerate and the leading energy and chemical company in Korea, has been engaged in the innovative discovery and development of novel therapeutic compounds in the field of neuroscience in order to treat CNS disorders including epilepsy, depression, anxiety, schizophrenia, Parkinson's disease, and other neurodegenerative disorders. In addition to the CNS area of research, SK Life Science is working on the discovery and development of novel therapeutic compounds for the treatment of metabolic diseases. ABOUT PATHEON Patheon Inc. (TSX:PTI; www.patheon.com) is a leading global provider of contract development and manufacturing services to the global pharmaceutical industry. Patheon prides itself in providing the highest quality products and services to more than 300 of the world's leading pharmaceutical and biotechnology companies. Patheon's services range from preclinical development through commercial manufacturing of a full array of dosage forms including parenteral, solid, semi-solid and liquid forms. Patheon uses many innovative technologies including single-use disposables, Liquid-Filled Hard Capsules and a variety of modified release technologies. Patheon's comprehensive range of fully integrated Pharmaceutical Development Services includes pre-formulation, formulation, analytical development, clinical manufacturing, scale-up and commercialization. Patheon can take customers direct to clinic with global clinical packaging and distribution services and Patheon's Quick to Clinic(TM) programs can accelerate early phase development project to clinical trials while minimizing the consumption of valuable API. Patheon's integrated development and manufacturing network of 11 facilities, and 6 development centers across North America and Europe, strives to ensure that customer products can be launched with confidence anywhere in the world. Caution Concerning Forward-Looking Statements This news release may contain forward-looking statements which reflect management's expectations regarding the Company's future growth of operations, performance (both operational and financial) and business prospects and opportunities. These statements are made in the context of the risks and uncertainties that are outlined in the Company's public documents, which can be accessed on our website at www.patheon.com or on SEDAR at www.sedar.com. %SEDAR: 00001700E For further information: Mr. Wes Wheeler, President & Chief Executive Officer, Tel: (905) 812-2112, Email: firstname.lastname@example.org; Mr. Terry Novak, President of North America, Chief Marketing Officer, Tel: (862) 207-1262, Email: email@example.com; Ms. Jean Treadwell, Investor Relations, Tel: (905) 816-8344, Email: firstname.lastname@example.org CO: Patheon Inc. ST: Ontario NI: MTC ORDER -0- Jul/08/2008 11:00 GMT
Russian International Reserves Fall $15.7 Billion in Week to Dec. 19
SK Life Science, Inc. Selects Patheon as Development Services
Press spacebar to pause and continue. Press esc to stop.